LENZ Therapeutics, Inc.

LENZNASDAQHealthcare● Active

$6.73

$-0.28(-3.99%)

Market Cap$211015072

P/E Ratio—

52W High$50.4

52W Low$6.61

Avg Volume936K

Open$7.09

Beta1.47

Free Cash Flow Financials Revenue

LENZ Therapeutics, Inc. (LENZ) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LENZ · free cash flow · updated Jun 8, 2026

Core FCF metrics

LENZ · FCF · TTM · margin & CAGR

Free cash flow was −$70.0M for FY2025 (fiscal year ending 2025-12-31), down 16.9% year-over-year The FCF margin was -366.7%.

FY2025 Free Cash Flow−$70.0M▼ -16.9% YoY

Trailing 12M (TTM)−$87.4Mtrailing 4 quarters sum

FCF Margin-366.7%−$70.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LENZ · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$69.2M(1M)−$70.0M▼ 16.9%-366.7%

FY2024−$59.4M(0M)−$59.9M▲ +0.9%—

FY2023−$60.4M(0M)−$60.4M▲ +36.1%—

FY2022−$88.0M(7M)−$94.6M▼ 61.4%-630.5%

FY2021−$52.9M(6M)−$58.6M▼ 470.7%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LENZ · P/FCF · FCF yield · FCF per share

LENZ Therapeutics, Inc. (LENZ) reported negative free cash flow of −$0.07B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LENZ · cash flow statement · operating / investing / financing

For FY2025, LENZ Therapeutics, Inc. generated −$69.2M in operating cash flow and spent 1M in capital expenditures, yielding −$70.0M in free cash flow.

Operating Activities

−$69.2M

Cash from core business operations

2025-12-31

Investing Activities

−$75.7M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$149.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$69.2M) − |CapEx| (1M) = FCF (−$70.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LENZ vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

LENZ Therapeutics, Inc.YOU

LENZ

−$70.0M-16.9%-366.7%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

LENZ Therapeutics, Inc. (LENZ) reported free cash flow of −$70.0M for FY2025 (fiscal year ending 2025-12-31), down 16.9% year-over-year. The FCF margin was -366.7%.

LENZ Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LENZ free cash flow · 8 questions

LENZ Therapeutics, Inc. free cash flow was −$70.0M for FY2025, down 16.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$87.4M.

LENZ free cash flowLENZ FCFLENZ FCF 2025LENZ free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · LENZ Therapeutics, Inc. · LENZ Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026